The first five-year cumulative revenue (2017–2021) global allergy diagnostics market is projected to reach US$ 5,417.6 Mn, as compared to a significantly higher cumulative revenue total of the latter five years of the forecast period (2022–2026). The inhaled allergen segment in the global allergy diagnostics market is estimated to account for the major revenue share of 48.3% in 2017.
Allergies are the result of an individual’s immune system responding to a substance, and a person becomes allergic when the body develops antigens against the substance. In addition, upon repeated exposure, the severity of the reaction may increase. Hypersensitiveness is usually triggered by allergens such as foods, pollen, dust mites, pet hair, molds, etc. Allergies can develop in any individual, regardless of age or gender, and can lead to major chronic diseases if left untreated. Majority of allergies are genetic, depending on one or both parents being allergic to any allergens. Symptoms include itchy eyes, itchy ears and throat, skin reactions, running or stuffy nose, nasal itching, wheezing, and diarrhea.
According to research and development, ‘hygiene hypothesis’ is a major factor driving the growth of the global allergy diagnostics market. This hypothesis states that individuals who lack early childhood exposure to infectious agents, parasites, or allergens may be more susceptible to allergies and associated diseases, due to restricted early development of the immune system. Alarming rise in environmental pollution levels, the prevalence of allergic conditions, increasing global aging population, changing lifestyle and related disorders, changing food habits, and longer pollen seasons due to climatic changes are some other major factors fueling the growth of the global allergy diagnostics market.
However, chances of false-positive results are high at the time of allergic diagnostic tests, which is hampering the growth of the global allergy diagnostics market to a significant extent. In addition, high investment cost for R&D and stringent government regulations are other factors impacting global market growth.
Companies profiled in the report are BioMerieux SA, Danaher Corporation, Hitachi Chemical Diagnostics Inc. Siemens AG, Thermo Fisher Scientific Inc., Stallergenes Greer, HOB Biotech Group Co. Ltd., HYCOR Biomedical, Lincoln Diagnostics Inc.
